Statements (36)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
FL T3 inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:café |
54611000
|
| gptkbp:clinical_trial |
Phase 1
Phase 2 Phase 3 |
| gptkbp:developer |
gptkb:Astellas_Pharma
|
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water soluble in methanol |
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:enemy |
CHEMB L2101550
|
| gptkbp:financial_products |
D B11763
|
| https://www.w3.org/2000/01/rdf-schema#label |
Gilteritinib
|
| gptkbp:ingredients |
C22 H24 Cl N5 O2 S
|
| gptkbp:is_atype_of |
L01 X X40
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:lifespan |
approximately 6 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
Xospata
|
| gptkbp:metabolism |
liver
|
| gptkbp:nutritional_value |
approximately 90%
|
| gptkbp:rounds |
urine
|
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea diarrhea thrombocytopenia |
| gptkbp:targets |
FL T3
|
| gptkbp:type_of |
1256580-58-4
|
| gptkbp:weight |
445.97 g/mol
|
| gptkbp:year |
gptkb:2018
|
| gptkbp:bfsParent |
gptkb:Genzyme_Genetics
|
| gptkbp:bfsLayer |
5
|